Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2017

01.06.2017 | short review

American Society of Hematology 2016 annual meeting

Progress in myelodysplastic syndromes

verfasst von: MBA Univ.-Prof. Dr. Michael Pfeilstöcker

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

For heterogeneous myelodysplastic syndromes (MDS), patient management is still a challenge. Despite the progress achieved in recent years, there is need for improvement at least for specific situations such as failure of hypomethylating agents or in patients with thrombocytopenia or with anemia failing erythropoiesis stimulating agents. This review covers studies for MDS presented at the American Society of Hematology (ASH) 2016 annual meeting. New treatment approaches, for which results from phase 1/2 studies were reported, will now move into phase 3 and hopefully into clinical practice in the future. Choosing the right agent and individualizing treatment will be the next challenges.
Literatur
1.
Zurück zum Zitat Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91(1):76–89. CrossRefPubMed Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91(1):76–89. CrossRefPubMed
2.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. CrossRefPubMed Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. CrossRefPubMed
3.
Zurück zum Zitat Malcovati L, Gallì A, Travaglino E, et al. Predictive value of mutation analysis in the diagnostic approach to patients with unexplained cytopenia. Blood. 2016;128:298. Malcovati L, Gallì A, Travaglino E, et al. Predictive value of mutation analysis in the diagnostic approach to patients with unexplained cytopenia. Blood. 2016;128:298.
4.
Zurück zum Zitat Al-Issa K, Zarzour A, Radivoyevitch T, et al. Incorporation of molecular data into the current prognostic models in treated patients with myelodysplastic syndromes: Which model is the best? Blood. 2016;128:50. Al-Issa K, Zarzour A, Radivoyevitch T, et al. Incorporation of molecular data into the current prognostic models in treated patients with myelodysplastic syndromes: Which model is the best? Blood. 2016;128:50.
6.
Zurück zum Zitat Bhatt ST, Monlish D, Duncavage EJ, et al. Toll like receptor 2/6 but not 1/2 signaling promotes leukemogenesis in a mouse model of myelodysplastic syndrome. Blood. 2016;128:1970. Bhatt ST, Monlish D, Duncavage EJ, et al. Toll like receptor 2/6 but not 1/2 signaling promotes leukemogenesis in a mouse model of myelodysplastic syndrome. Blood. 2016;128:1970.
7.
Zurück zum Zitat Garcia-Manero G, Montalban-Bravo G, Yang H, et al. A clinical study of OPN-305, a toll-like receptor 2 (TLR-2) antibody, in patients with lower risk myelodysplastic syndromes (MDS) that have received prior Hypomethylating agent (HMA) therapy. Blood. 2016;128:227. CrossRef Garcia-Manero G, Montalban-Bravo G, Yang H, et al. A clinical study of OPN-305, a toll-like receptor 2 (TLR-2) antibody, in patients with lower risk myelodysplastic syndromes (MDS) that have received prior Hypomethylating agent (HMA) therapy. Blood. 2016;128:227. CrossRef
8.
Zurück zum Zitat Taher AT, Origa R, Perrotta S, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or MDS: results of the randomized, phase II E.C.L.I.P.S.E. study. Blood. 2016;128:1285. Taher AT, Origa R, Perrotta S, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or MDS: results of the randomized, phase II E.C.L.I.P.S.E. study. Blood. 2016;128:1285.
9.
Zurück zum Zitat Taher AT, Origa R, Perrotta S, et al. Improved patient-reported outcomes with a film-coated versus dispersible tablet formulation of deferasirox: results from the randomized, phase II E.C.L.I.P.S.E. study. Blood. 2016;128:850. Taher AT, Origa R, Perrotta S, et al. Improved patient-reported outcomes with a film-coated versus dispersible tablet formulation of deferasirox: results from the randomized, phase II E.C.L.I.P.S.E. study. Blood. 2016;128:850.
10.
Zurück zum Zitat Rose C, Fitoussi O, Gyan E, et al. Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload: the Rythmex study. Blood. 2016;128:2008. Rose C, Fitoussi O, Gyan E, et al. Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload: the Rythmex study. Blood. 2016;128:2008.
11.
Zurück zum Zitat Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo (PBO)-controlled double-blind trial of darbepoetin alfa in the treatment of anemia in patients with low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDS). Blood. 2016;128:2010. Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo (PBO)-controlled double-blind trial of darbepoetin alfa in the treatment of anemia in patients with low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDS). Blood. 2016;128:2010.
12.
Zurück zum Zitat Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76. CrossRefPubMed Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76. CrossRefPubMed
13.
Zurück zum Zitat Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) Myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988–96. CrossRefPubMed Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) Myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988–96. CrossRefPubMed
14.
Zurück zum Zitat Basiorka AA, McGraw KL, De Ceuninck L, et al. Lenalidomide stabilizes the erythropoietin receptor by inhibiting the E3 ubiquitin ligase RNF41. Cancer Res. 2016;76:3531–40. CrossRefPubMedPubMedCentral Basiorka AA, McGraw KL, De Ceuninck L, et al. Lenalidomide stabilizes the erythropoietin receptor by inhibiting the E3 ubiquitin ligase RNF41. Cancer Res. 2016;76:3531–40. CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat List AF, Sun Z, Verma A, et al. Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [del(5q)] Myelodysplastic syndrome (MDS): results of the E2905 intergroup study-an ECOG-ACRIN cancer research group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health. Blood. 2016;128:223. List AF, Sun Z, Verma A, et al. Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [del(5q)] Myelodysplastic syndrome (MDS): results of the E2905 intergroup study-an ECOG-ACRIN cancer research group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health. Blood. 2016;128:223.
16.
Zurück zum Zitat van de Loosdrecht AA, Chitu DA, Cremers EMP, et al. Lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor shows efficacy in patients with low and intermediate-1 risk Myelodysplastic syndrome with or without del 5q, refractory or unlikely to respond to erythropoietin. Results of a HOVON89 phase II randomized multicenter study. (EudraCT 2008-002195-10). Blood. 2016;128:224. van de Loosdrecht AA, Chitu DA, Cremers EMP, et al. Lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor shows efficacy in patients with low and intermediate-1 risk Myelodysplastic syndrome with or without del 5q, refractory or unlikely to respond to erythropoietin. Results of a HOVON89 phase II randomized multicenter study. (EudraCT 2008-002195-10). Blood. 2016;128:224.
17.
Zurück zum Zitat Platzbecker U, Germing U, Götze U, et al. Luspatercept increases hemoglobin and reduces transfusion burden in patients with low-intermediate risk myelodysplastic syndromes (MDS): long-term results from phase 2 PACE-MDS study. Blood. 2016;128:3168. Platzbecker U, Germing U, Götze U, et al. Luspatercept increases hemoglobin and reduces transfusion burden in patients with low-intermediate risk myelodysplastic syndromes (MDS): long-term results from phase 2 PACE-MDS study. Blood. 2016;128:3168.
18.
Zurück zum Zitat Boch T, Luft T, Mossner M, et al. Safety and efficacy of the CD95-ligand inhibitor APG101 in transfusion-dependent patients with low risk MDS: results from a phase I study. Blood. 2016;128:228. Boch T, Luft T, Mossner M, et al. Safety and efficacy of the CD95-ligand inhibitor APG101 in transfusion-dependent patients with low risk MDS: results from a phase I study. Blood. 2016;128:228.
19.
Zurück zum Zitat Jabbour EJ, Short NJ, Huang X, et al. A randomized phase II study of low-dose decitabine versus azacitidine in patients with low- or intermediate-1-risk myelodysplastic syndromes: a report on behalf of the MDS clinical research consortium. Blood. 2016;128:226. Jabbour EJ, Short NJ, Huang X, et al. A randomized phase II study of low-dose decitabine versus azacitidine in patients with low- or intermediate-1-risk myelodysplastic syndromes: a report on behalf of the MDS clinical research consortium. Blood. 2016;128:226.
20.
Zurück zum Zitat Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–7. CrossRefPubMedPubMedCentral Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–7. CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib (AG-221), a potent oral inhibitor of mutant Isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS). Blood. 2016;128:343. Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib (AG-221), a potent oral inhibitor of mutant Isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS). Blood. 2016;128:343.
22.
Zurück zum Zitat DiNardo CD, de Botton S, Stein EM, et al. Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of mutant IDH1. Blood. 2016;128:1070. DiNardo CD, de Botton S, Stein EM, et al. Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of mutant IDH1. Blood. 2016;128:1070.
24.
Zurück zum Zitat Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–8. CrossRefPubMed Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–8. CrossRefPubMed
25.
Zurück zum Zitat Garcia-Manero G, Daver NG, Montalban-Bravo G, et al. A phase II study evaluating the combination of nivolumab (Nivo) or Ipilimumab (Ipi) with azacitidine in pts with previously treated or untreated myelodysplastic syndromes (MDS). Blood. 2016;128:344. Garcia-Manero G, Daver NG, Montalban-Bravo G, et al. A phase II study evaluating the combination of nivolumab (Nivo) or Ipilimumab (Ipi) with azacitidine in pts with previously treated or untreated myelodysplastic syndromes (MDS). Blood. 2016;128:344.
26.
Zurück zum Zitat Garcia-Manero G, Tallman MS, Martinelli G, et al. Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment. Blood. 2016;128:345. Garcia-Manero G, Tallman MS, Martinelli G, et al. Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment. Blood. 2016;128:345.
Metadaten
Titel
American Society of Hematology 2016 annual meeting
Progress in myelodysplastic syndromes
verfasst von
MBA Univ.-Prof. Dr. Michael Pfeilstöcker
Publikationsdatum
01.06.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0330-8

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe